Drug shortages are becoming commonplace in the U.S. Data from a new pharmaceutical industry tracking firm, Qyobo, shows hundreds of drugs are still in short supply – some well over a year — and our dependence on imports grows, including from labs on the receiving end of lackluster FDA inspections.
The United States is facing an unprecedented drug shortage, with a record 323 active drug shortages at the start of 2024 — the highest number since 2001.
The foreign labs in China and India that make the branded drugs for CVS pharmacies nationwide are coming under increased scrutiny for unsafe manufacturing practices.
When drugs are pulled from pharmacy shelves, it’s somewhat of a well-kept secret that it is the pharmaceutical company that voluntarily warns buyers of the potential harm from the defect.
Generic drug exporter Zydus Lifesciences received poor marks again in April following a Food and Drug Administration inspection of its lab in Vadodara, a city in Gujarat state on India’s western coast.
The Veterans Health Administration (VHA) banned the use of plastic syringes made in China on April 23 due to safety concerns, ahead of a warning letter dated April 24 to Ohio-based importer Cardinal Health by the Food and Drug Administration.
USTR Katherine Tai sat for a two hours-plus hearing with the House Ways and Means Committee on Tuesday to discuss trade matters and was met early on by some staunch criticism.
Despite spending over $600 billion on prescription drugs, the number of drugs in shortage rose to a near-record total of 301 active medication shortages at the end of 2023.
America’s largest generic drug supplier, Aurobindo, is riddled with safety and quality issues, including ties to overseas suppliers with links to China’s military.
Roughly 40 congressional staff members had a chance to meet with and hear from industry leaders as diverse as Florida farmers to multinational corporations in the renewable energy space about the trials and tribulations of competing with emerging markets that play by different rules. And often break existing ones.
